Organon & Co
STU : 7XP€12.24+0.25%Oct 16 close
Financials
Condensed Consolidated Balance Sheets
USD · reported units. Click a value to inspect its source.
| Reported line item | Jun 30, 2026 (current) | Dec 31, 2025 |
|---|---|---|
| Statement of Financial Position [Abstract] | ||
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | ||
| Accounts receivable (net of allowance for doubtful accounts of $13 in 2026 and $12 in 2025) | ||
| Inventories (excludes inventories of $273 in 2026 and $236 in 2025 classified in Other assets) | ||
| Other current assets | ||
| Assets held for sale | ||
| Total Current Assets | ||
| Property, plant and equipment, net | ||
| Goodwill | ||
| Intangibles, net | ||
| Other assets | ||
| Noncurrent assets held for sale | ||
| Total Assets | ||
| Liabilities and Equity | ||
| Current Liabilities: | ||
| Current portion of long-term debt and short-term borrowings | ||
| Trade accounts payable | ||
| Accrued and other current liabilities | ||
| Income taxes payable | ||
| Liabilities held for sale | ||
| Total Current Liabilities | ||
| Long-term debt | ||
| Deferred income taxes | ||
| Other noncurrent liabilities | ||
| Noncurrent liabilities held for sale | ||
| Total Liabilities | ||
| Contingencies (Note 15) | — | — |
| Organon & Co. Stockholders’ Equity: | ||
| Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 262,609 in 2026 and 260,316 in 2025 | ||
| Additional paid-in capital | ||
| Retained earnings | ||
| Accumulated other comprehensive loss | ||
| Total Stockholders’ Equity | ||
| Total Liabilities and Stockholders’ Equity |
30 line items · 2 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.
Arithmetic validation is incomplete for this statement. Source values remain individually inspectable.